Tsumura & Co. (OTCMKTS:TSMRF – Get Free Report) is anticipated to issue its results before the market opens on Monday, November 9th. Analysts expect Tsumura & Co. to post earnings of $0.6940 per share and revenue of $342.34 million for the quarter.
Tsumura & Co. Price Performance
OTCMKTS TSMRF opened at $23.20 on Monday. Tsumura & Co. has a 52 week low of $23.20 and a 52 week high of $25.75. The stock has a fifty day moving average of $23.20 and a 200-day moving average of $23.20.
Tsumura & Co. Company Profile
Tsumura & Co is a Japan-based pharmaceutical company specializing in Kampo medicines, traditional Japanese formulations derived from classical Chinese herbal medicine. The company develops, manufactures, and markets prescription Kampo products, primarily in the form of standardized herbal extracts used by healthcare professionals in Japan.
Its product portfolio is made from medicinal plants and other crude drug ingredients sourced, processed, and formulated under pharmaceutical quality standards.
Featured Stories
- Five stocks we like better than Tsumura & Co.
- Uranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
Receive News & Ratings for Tsumura & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tsumura & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
